What was the most successful biotech IPO of 2014?
Look no further than Ultragenyx. A special report by Fierce Biotech says that the Novato, Calif., maker of treatments for rare and ultra-rare diseases took the top spot for the year, raising nearly $122 million in the offering of more than 5.8 million shares.
But Ultragenyx isn’t alone in California, which claims five spots on the top-10 list. Also represented are companies in Massachusetts, Texas and the Netherlands. Here’s a look at the full list:
1. Ultragenyx Pharmaceutical (RARE)
Headquarters: Novato, Calif. IPO price: $21 Close Sept. 30: $56.60 Change: Up 170% Raised: $122 million
2. ZS Pharma (ZSPH)
Headquarters: Coppell, Texas IPO price: $18 Close Sept. 30: $39.23 Change: Up 118% Raised: $107 million
3. Auspex Pharmaceuticals (ASPX)
Headquarters: La Jolla, Calif. IPO price: $12 Close Sept. 30: $25.67 Change: Up 114% Raised: $84 million
4. Avalanche Biotechnologies (AAVL)
Headquarters: Menlo Park, Calif. IPO price: $17 Close Sept. 30: $34.19 Change: Up 101% Raised: $102 million
5. Sage Therapeutics (SAGE)
Headquarters: Cambridge, Mass. IPO price: $18 Close Sept. 30: $31.50 Change: Up 75% Raised: $90 million
6. Kite Pharma (KITE)
Headquarters: Santa Monica, Calif. IPO price: $17 Close Sept. 30: $28.50 Change: Up 68% Raised: $128 million
7. Otonomy (OTIC)
Headquarters: San Diego IPO price: $16 Close Sept. 30: $24 Change: Up 50% Raised: $100 million
8. Zafgen (ZFGN)
Headquarters: Boston IPO price: $16 Close Sept. 30: $19.65 Change: Up 23% Raised: $102.7 million
9. ProQR Therapeutics (PRQR)
Headquarters: Leiden, Netherlands IPO price: $13 Close Sept. 30: $17.19 Change: Up 32% Raised: $98 million
10. Radius Health (RDUS)
Headquarters: Waltham, Mass. IPO price: $8 Close Sept. 30: $21 Change: Up 163% Raised: $52 million
